RETA — Reata Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge Cap
- $6.52bn
- $6.27bn
- $2.22m
Reata Pharmaceuticals Inc expected to post a loss of $2.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tupperware, Netflix, Copper miners
Reata gains as Stifel raises PT on genetic disorder drug potential
Reata Pharma hits 1-year high as genetic disorder drug gets FDA nod
Reata shares hit 1-year high after surprise FDA nod for rare disease drug (updated)
U.S. STOCKS ON THE MOVE-Wendy's, HP, Sanofi
Reata shares surge after surprise FDA nod for rare disease drug
U.S. STOCKS ON THE MOVE-Reata Pharma, Tesla, Caterpillar
Reata Pharma soars as genetic disorder drug gets FDA nod
Press Digest: Wall Street Journal - March 1
U.S. FDA approves Reata's rare genetic disorder drug (updated)
U.S. FDA approves Reata's rare genetic disorder drug
Brief: Reata Pharmaceuticals Announces FDA Approval Of Skyclarys™ (Omavaloxolone), The First And Only Drug Indicated For Patients With Friedreich’S Ataxia
FDA neurosciences chief Billy Dunn to leave immediately, analysts raise concern
Reata Pharmaceuticals Inc expected to post a loss of $2.22 a share - Earnings Preview
Reata Pharma rises on regulatory update for genetic disease drug
Reata Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Reata Pharmaceuticals Reports Q3 Adjusted Loss Of $1.47 Per Share
Reata Pharmaceuticals Inc expected to post a loss of $2.18 a share - Earnings Preview